Treatment Options for Hirsutism: A Systematic Review and Network Meta-Analysis

@article{Barrionuevo2018TreatmentOF,
  title={Treatment Options for Hirsutism: A Systematic Review and Network Meta-Analysis},
  author={Patricia Barrionuevo and Mohammed Nabhan and Osama Altayar and Zhen Wang and Patricia J. Erwin and Noor Asi and Kathryn A. Martin and Mohammad Hassan Murad},
  journal={The Journal of Clinical Endocrinology \& Metabolism},
  year={2018},
  volume={103},
  pages={1258–1264}
}
Background Several pharmacologic treatments for hirsutism are used in practice; however, their relative efficacy is unclear. Methods We searched MEDLINE, EMBASE, and CENTRAL through January 2017 for randomized controlled trials (RCTs) with follow-up of at least 6 months that evaluated antiandrogens, insulin sensitizers, and oral contraceptives in women with hirsutism. Independent pairs of reviewers selected and appraised trials. Random-effects network meta-analysis was used to compare… Expand
Efficacy of Treatments for Polycystic Ovarian Syndrome Management in Adolescents
TLDR
Metformin and OCP as monotherapy or in combination with other interventions compared with placebo can reduce hirsutism scores, but none of these medications lead to effective menstrual cycle regulation or weight reduction, however, the use of OCP leads to worse cardiometabolic risk factors. Expand
Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline.
TLDR
This evidence-based guideline recommends testing for elevated androgen levels in all women with an abnormal hirsutism score and recommends against antiandrogen monotherapy unless adequate contraception is used and against using insulin-lowering drugs. Expand
What are the most effective pharmacologic treatments for hirsutism in women?
There is no single most effective agent for the treatment of hirsutism in women. Pharmacotherapies including spironolactone, metformin, finasteride, flutamide, topical eflornithine cream, and oralExpand
Response to the letter to the editor; Androgenetic alopecia; drug safety and therapeutic strategies
TLDR
The concern is perhaps as ideological as it is medical, as the discussion regarding the therapeutic approach of androgenic alopecia relates to the risk–benefit ratio, the benefit being related to an esthetic aspect, while the risk is related to very real organic adverse effects. Expand
Anti-androgenic therapy in young patients and its impact on intensity of hirsutism, acne, menstrual pain intensity and sexuality - a preliminary study.
TLDR
Surprisingly, according to the research, dienogest does not have any impact on body hairiness and Cyproterone and drospirenone turned out as the most effective drugs in treating hirsutism. Expand
Finasteride and androgenic alopecia; from therapeutic options to medical implications
TLDR
Several factors presented in this paper appear to explain finasteride inconsistency regarding its therapeutic and side effects, and should be further investigated and used to categorize subjects into distinct subgroups, either predisposed to adverse reactions or more tolerant of the finasterid administration. Expand
A safety evaluation of current medications for adult women with the polycystic ovarian syndrome not pursuing pregnancy.
TLDR
There is no solid evidence supporting that the use of combined oral contraceptives in women with PCOS increases the risk of cardiovascular or thromboembolic events compared with the general population. Expand
Androgens in women: Hormone-modulating therapies for skin disease.
TLDR
Despite the ubiquity of hormone-modulating therapies used for AMCDs, this review highlights the need for more rigorous studies to evaluate these therapies for acne, hirsutism, and female pattern hair loss. Expand
An Update on Contraception in Polycystic Ovary Syndrome
TLDR
Individual risk assessment is the key in order to avoid unfavorable outcomes related to COC use in women with PCOS, and patients should be re-assessed at consecutive visits if any baseline cardiometabolic risk factor is present. Expand
Medical treatment and comorbidity in polycystic ovary syndrome: An updated review
TLDR
The present article gives an update regarding established and upcoming medical treatment for PCOS and for comorbidities of PCOS. Expand
...
1
2
...

References

SHOWING 1-10 OF 27 REFERENCES
Clinical review: Antiandrogens for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials.
TLDR
Weak evidence suggests antiandrogens are mildly effective agents for the treatment of hirsutism, and they appear superior to monotherapy with contraceptives and metformin, respectively. Expand
Clinical review: Insulin sensitizers for the treatment of hirsutism: a systematic review and metaanalyses of randomized controlled trials.
TLDR
Imprecise and inconsistent evidence of low to very low quality suggests that insulin sensitizers provide limited or no important benefit for women with hirsutism. Expand
Metformin or Oral Contraceptives for Adolescents With Polycystic Ovarian Syndrome: A Meta-analysis
TLDR
A systematic review and meta-analysis of randomized controlled trials to evaluate the use of metformin versus oral contraceptive pills (OCPs) for the treatment of PCOS in adolescents aged 11 to 19 years concluded that treatment choice should be guided by patient values and preferences while balancing potential side effects. Expand
Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne.
TLDR
There is some evidence to show that spironolactone is an effective treatment to decrease the degree of hirsutism but there was no evidence for effectiveness for the treatment of acne vulgaris. Expand
Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome.
TLDR
Up to 12-months treatment with the OCP is associated with an improvement in menstrual pattern and serum androgen levels compared with metformin; but met formin treatment results in a reduction in fasting insulin and lower triglyceride levels than with theOCP. Expand
Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline.
TLDR
The Task Force suggests testing for elevated androgen levels in women with moderate or severe hirsutism or hirsUTism of any degree when it is sudden in onset, rapidly progressive, or associated with other abnormalities such as menstrual dysfunction, obesity, or clitoromegaly. Expand
A comparative systematic review of Yasmin (drospirenone pill) versus standard treatment options for symptoms of polycystic ovary syndrome.
TLDR
It is suggested that DRSP was effective in modulating hormones, insulin and lipid metabolism in women with PCOS and for the PCOS patients with IR, obesity or high LH/FSH ratio, DRSP combines with metformin maybe more effective than use DRSP alone. Expand
Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society.
TLDR
Evidence-based diagnostic and treatment strategies that address not only the amelioration of hirsutism but also the treatment of the underlying etiology is essential for the proper management of affected women, especially considering that hirsUTism is, in most cases, a chronic disorder needing long-term follow-up. Expand
Lifestyle changes in women with polycystic ovary syndrome.
TLDR
Lifestyle intervention improves body composition, hyperandrogenism (high male hormones and clinical effects) and insulin resistance in women with PCOS and provides benefits when compared to minimal treatment for secondary outcomes. Expand
Psychological morbidity in women referred for treatment of hirsutism.
TLDR
It is suggested that a proportion of women with hirsutism experiences psychological and social difficulties, and that factors other than their dermatological status play an important part in their psychological difficulties. Expand
...
1
2
3
...